New targeted therapy shows promise for patients with advanced bladder cancer
FX-909, a first-in-class investigational oral small molecule inhibitor of peroxisome proliferator-activated receptor gamma (PPARG), showed early signs of clinical benefit in patients with advanced urothelial carcinoma, according ...
Oct 22, 2025
0
9









